Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis

Borja Hernández-Breijo, Chamaida Plasencia-Rodríguez, Victoria Navarro-Compán, Ana Martínez-Feito, Andrea Jochems, Eva L. Kneepkens, Gerrit J. Wolbink, Theo Rispens, Cristina Diego, Dora Pascual-Salcedo, Alejandro Balsa

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: The aim of our study was to investigate the influence of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and clinical response to tumour necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) patients. Methods: Prospective observational study during 1 year with 2 cohorts (Madrid and Amsterdam) including 180 axSpA patients treated with standard doses of infliximab or adalimumab. Patients were stratified by BMI, being 78 (43%) normal weight (18.5-24.9 kg/m 2 ) and 102 (57%) overweight/obese (≥ 25.0 kg/m 2 ). After the first year of treatment, TNFi trough levels were measured by capture ELISA. Clinical response to TNFi was defined as FOR VERIFICATION BASDAI ≥ 2 and clinical remission as BASDAI < 2 and CRP ≤ 5 mg/L. Logistic regression models were employed to analyse the association between concomitant csDMARDs and BMI with drug levels and clinical response. Results: Seventy-nine patients (44%) received concomitant csDMARDs. The administration of concomitant csDMARDs (OR 3.82; 95% CI 1.06-13.84) and being normal weight (OR 18.38; 95% CI 2.24-150.63) were independently associated with serum TNFi drug persistence. Additionally, the use of concomitant csDMARDs contributed positively to achieve clinical response (OR 7.86; 95% CI 2.39-25.78) and remission (OR 4.84; 95% CI 1.09-21.36) in overweight/obese patients, but no association was found for normal-weight patients (OR 1.10; 0.33-3.58). Conclusions: The use of concomitant csDMARDs with TNFi may increase the probability of achieving clinical response in overweight/obese axSpA patients. Further research studies including larger cohorts of patients need to be done to confirm it.
Original languageEnglish
Article number66
JournalArthritis Research and Therapy
Volume21
Issue number1
DOIs
Publication statusPublished - 2019

Cite this

Hernández-Breijo, B., Plasencia-Rodríguez, C., Navarro-Compán, V., Martínez-Feito, A., Jochems, A., Kneepkens, E. L., ... Balsa, A. (2019). Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. Arthritis Research and Therapy, 21(1), [66]. https://doi.org/10.1186/s13075-019-1849-3
Hernández-Breijo, Borja ; Plasencia-Rodríguez, Chamaida ; Navarro-Compán, Victoria ; Martínez-Feito, Ana ; Jochems, Andrea ; Kneepkens, Eva L. ; Wolbink, Gerrit J. ; Rispens, Theo ; Diego, Cristina ; Pascual-Salcedo, Dora ; Balsa, Alejandro. / Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. In: Arthritis Research and Therapy. 2019 ; Vol. 21, No. 1.
@article{0990cdac15ca4a02a3ced3c6e77ec8e1,
title = "Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis",
abstract = "Background: The aim of our study was to investigate the influence of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and clinical response to tumour necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) patients. Methods: Prospective observational study during 1 year with 2 cohorts (Madrid and Amsterdam) including 180 axSpA patients treated with standard doses of infliximab or adalimumab. Patients were stratified by BMI, being 78 (43{\%}) normal weight (18.5-24.9 kg/m 2 ) and 102 (57{\%}) overweight/obese (≥ 25.0 kg/m 2 ). After the first year of treatment, TNFi trough levels were measured by capture ELISA. Clinical response to TNFi was defined as FOR VERIFICATION BASDAI ≥ 2 and clinical remission as BASDAI < 2 and CRP ≤ 5 mg/L. Logistic regression models were employed to analyse the association between concomitant csDMARDs and BMI with drug levels and clinical response. Results: Seventy-nine patients (44{\%}) received concomitant csDMARDs. The administration of concomitant csDMARDs (OR 3.82; 95{\%} CI 1.06-13.84) and being normal weight (OR 18.38; 95{\%} CI 2.24-150.63) were independently associated with serum TNFi drug persistence. Additionally, the use of concomitant csDMARDs contributed positively to achieve clinical response (OR 7.86; 95{\%} CI 2.39-25.78) and remission (OR 4.84; 95{\%} CI 1.09-21.36) in overweight/obese patients, but no association was found for normal-weight patients (OR 1.10; 0.33-3.58). Conclusions: The use of concomitant csDMARDs with TNFi may increase the probability of achieving clinical response in overweight/obese axSpA patients. Further research studies including larger cohorts of patients need to be done to confirm it.",
author = "Borja Hern{\'a}ndez-Breijo and Chamaida Plasencia-Rodr{\'i}guez and Victoria Navarro-Comp{\'a}n and Ana Mart{\'i}nez-Feito and Andrea Jochems and Kneepkens, {Eva L.} and Wolbink, {Gerrit J.} and Theo Rispens and Cristina Diego and Dora Pascual-Salcedo and Alejandro Balsa",
year = "2019",
doi = "10.1186/s13075-019-1849-3",
language = "English",
volume = "21",
journal = "Arthritis Research & Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

Hernández-Breijo, B, Plasencia-Rodríguez, C, Navarro-Compán, V, Martínez-Feito, A, Jochems, A, Kneepkens, EL, Wolbink, GJ, Rispens, T, Diego, C, Pascual-Salcedo, D & Balsa, A 2019, 'Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis' Arthritis Research and Therapy, vol. 21, no. 1, 66. https://doi.org/10.1186/s13075-019-1849-3

Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. / Hernández-Breijo, Borja; Plasencia-Rodríguez, Chamaida; Navarro-Compán, Victoria; Martínez-Feito, Ana; Jochems, Andrea; Kneepkens, Eva L.; Wolbink, Gerrit J.; Rispens, Theo; Diego, Cristina; Pascual-Salcedo, Dora; Balsa, Alejandro.

In: Arthritis Research and Therapy, Vol. 21, No. 1, 66, 2019.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis

AU - Hernández-Breijo, Borja

AU - Plasencia-Rodríguez, Chamaida

AU - Navarro-Compán, Victoria

AU - Martínez-Feito, Ana

AU - Jochems, Andrea

AU - Kneepkens, Eva L.

AU - Wolbink, Gerrit J.

AU - Rispens, Theo

AU - Diego, Cristina

AU - Pascual-Salcedo, Dora

AU - Balsa, Alejandro

PY - 2019

Y1 - 2019

N2 - Background: The aim of our study was to investigate the influence of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and clinical response to tumour necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) patients. Methods: Prospective observational study during 1 year with 2 cohorts (Madrid and Amsterdam) including 180 axSpA patients treated with standard doses of infliximab or adalimumab. Patients were stratified by BMI, being 78 (43%) normal weight (18.5-24.9 kg/m 2 ) and 102 (57%) overweight/obese (≥ 25.0 kg/m 2 ). After the first year of treatment, TNFi trough levels were measured by capture ELISA. Clinical response to TNFi was defined as FOR VERIFICATION BASDAI ≥ 2 and clinical remission as BASDAI < 2 and CRP ≤ 5 mg/L. Logistic regression models were employed to analyse the association between concomitant csDMARDs and BMI with drug levels and clinical response. Results: Seventy-nine patients (44%) received concomitant csDMARDs. The administration of concomitant csDMARDs (OR 3.82; 95% CI 1.06-13.84) and being normal weight (OR 18.38; 95% CI 2.24-150.63) were independently associated with serum TNFi drug persistence. Additionally, the use of concomitant csDMARDs contributed positively to achieve clinical response (OR 7.86; 95% CI 2.39-25.78) and remission (OR 4.84; 95% CI 1.09-21.36) in overweight/obese patients, but no association was found for normal-weight patients (OR 1.10; 0.33-3.58). Conclusions: The use of concomitant csDMARDs with TNFi may increase the probability of achieving clinical response in overweight/obese axSpA patients. Further research studies including larger cohorts of patients need to be done to confirm it.

AB - Background: The aim of our study was to investigate the influence of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and clinical response to tumour necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) patients. Methods: Prospective observational study during 1 year with 2 cohorts (Madrid and Amsterdam) including 180 axSpA patients treated with standard doses of infliximab or adalimumab. Patients were stratified by BMI, being 78 (43%) normal weight (18.5-24.9 kg/m 2 ) and 102 (57%) overweight/obese (≥ 25.0 kg/m 2 ). After the first year of treatment, TNFi trough levels were measured by capture ELISA. Clinical response to TNFi was defined as FOR VERIFICATION BASDAI ≥ 2 and clinical remission as BASDAI < 2 and CRP ≤ 5 mg/L. Logistic regression models were employed to analyse the association between concomitant csDMARDs and BMI with drug levels and clinical response. Results: Seventy-nine patients (44%) received concomitant csDMARDs. The administration of concomitant csDMARDs (OR 3.82; 95% CI 1.06-13.84) and being normal weight (OR 18.38; 95% CI 2.24-150.63) were independently associated with serum TNFi drug persistence. Additionally, the use of concomitant csDMARDs contributed positively to achieve clinical response (OR 7.86; 95% CI 2.39-25.78) and remission (OR 4.84; 95% CI 1.09-21.36) in overweight/obese patients, but no association was found for normal-weight patients (OR 1.10; 0.33-3.58). Conclusions: The use of concomitant csDMARDs with TNFi may increase the probability of achieving clinical response in overweight/obese axSpA patients. Further research studies including larger cohorts of patients need to be done to confirm it.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85061976742&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30786913

U2 - 10.1186/s13075-019-1849-3

DO - 10.1186/s13075-019-1849-3

M3 - Article

VL - 21

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

SN - 1478-6354

IS - 1

M1 - 66

ER -